Drug Trial Radar · NCT07920354
Comparative Efficacy of Luliconazole and Bifonazole Combined With Itraconazole in Dermatophytosis
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- University of FaisalabadAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this randomized controlled trial is to compare the efficacy of topical luliconazole with topical bifonazole in adults aged 18-60 years with dermatophytosis. All participants will receive oral itraconazole, while either topical luliconazole or topical bifonazole will be added according to their assigned treatment group. The main questions it aims to answer are: * Does topical luliconazole result in greater improvement in clinical severity, as measured by the DeASI score, compared with topical bifonazole? * Does topical luliconazole result in better mycological clearance on 10% KOH microscopy and lower relapse compared with topical bifonazole? Researchers will compare topical luliconazole with topical bifonazole, with oral itraconazole given to both groups, to assess differences in clinical improvement, mycological cure, and relapse. Participants will: * Receive oral itraconazole 100 mg once daily together with either topical luliconazole 1% or topical bifonazole 1% once daily for 28 days. * Attend follow-up visits at weeks 2, 4, and 6 for clinical assessment, DeASI scoring, and 10% KOH microscopy.
Conditions
- Tinea Corporis
- Tinea Cruris
- Tinea Faciei
Interventions
ItraconazoleDrug
Itraconazole 100 mg orally twice daily for 28 days. It will be administered to participants in both treatment groups.
Luliconazole Cream 1%Drug
Luliconazole 1% cream applied topically once daily for 28 days to the affected areas.
Bifonazole cream 1%Drug
Bifonazole 1% cream applied topically once daily for 28 days to the affected areas.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in DeASI score from baseline to Week 4Time frame: Baseline to Week 4
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Madinah Teaching Hospital
Faisalabad, Punjab Province, Pakistan
Madinah Teaching Hospital
Faisalabad, Punjab Province, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.